Immune checkpoints: A therapeutic target in triple negative breast cancer

Akhil Chawla; Anne V. Philips; Gheath Alatrash; Elizabeth Mittendorf

doi:10.4161/onci.28325

Immune checkpoints: A therapeutic target in triple negative breast cancer

Akhil Chawla, Anne V. Philips, Gheath Alatrash, Elizabeth Mittendorf^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

35 Scopus citations

Abstract

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

Original language	English (US)
Article number	e28325
Journal	OncoImmunology
Volume	3
Issue number	4
DOIs	https://doi.org/10.4161/onci.28325
State	Published - 2014
Externally published	Yes

Keywords

Biomarker
Immunotherapy
PD-L1
PI3K
Triple negative breast cancer

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/onci.28325

Cite this

@article{04dd6d5c2e9e4b2ab79ad01f64ee61ac,

title = "Immune checkpoints: A therapeutic target in triple negative breast cancer",

abstract = "Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.",

keywords = "Biomarker, Immunotherapy, PD-L1, PI3K, Triple negative breast cancer",

author = "Akhil Chawla and Philips, {Anne V.} and Gheath Alatrash and Elizabeth Mittendorf",

year = "2014",

doi = "10.4161/onci.28325",

language = "English (US)",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "4",

}

TY - JOUR

T1 - Immune checkpoints

T2 - A therapeutic target in triple negative breast cancer

AU - Chawla, Akhil

AU - Philips, Anne V.

AU - Alatrash, Gheath

AU - Mittendorf, Elizabeth

PY - 2014

Y1 - 2014

N2 - Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

AB - Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

KW - Biomarker

KW - Immunotherapy

KW - PD-L1

KW - PI3K

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84902590227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902590227&partnerID=8YFLogxK

U2 - 10.4161/onci.28325

DO - 10.4161/onci.28325

M3 - Comment/debate

C2 - 24843833

AN - SCOPUS:84902590227

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 4

M1 - e28325

ER -

Immune checkpoints: A therapeutic target in triple negative breast cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this